360head Stockiq
Global Intelligence Terminal
Loading live prices…
LIVE
--:--:--
AI-generated, informational and educational only. Not financial advice. Past performance does not indicate future results. Always do your own research.

ACADIA Pharmaceuticals Inc (ACAD)

Price $18.75 · +3.36% today · $3.2B market cap.

biotech_pharma
Strongest Overalllow risk← Back
Simulated history. Equities don't yet have ingested OHLCV, so the price chart and technical indicators below are illustrative (deterministic, labelled) — not real market history.
Price & Performance
$18.75 -28.7% over 1Y
Simulated history — illustrative, not real market data.
Today
+3.36%
1 week
-14.55%
1 month
-11.90%
1 year
-24.82%
Technical Analysis
RSI (14)
62.20
MACD
0.03
MACD signal
-0.11
MACD hist
0.14
SMA 20
17.95
SMA 50
18.26
EMA 20
18.07
ATR (14)
0.43
Support
17.17
Resistance
18.85
Bollinger upper
18.80
Bollinger lower
17.09

Indicators describe past price action — they do not predict future direction.

Fundamental Analysis
P/E ratio
8.95
Return on equity
28.03%
EBITDA
n/a
EPS (TTM)
2.10
Net debt
n/a
Net margin
30.13%
Gross margin
90.48%
Current ratio
3.82
Debt / Equity
0.00
Dividend yield
n/a
Operating margin
10.17%
Revenue growth (YoY)
49.76%
Risk Assessment
Ann. volatility
31.9%
Max drawdown
37.4%
Liquidity
Adequate market capitalization
Leverage
Debt/equity 0.0 (manageable)
Valuation
P/E 9×
Earnings
Earnings dates are not tracked in this release.
Concentration
Single-name equity — no diversification within the position.

Estimated annualized volatility 32% with a maximum drawdown of 37% over the available window.

Investment Thesis (generated summary)

ACADIA Pharmaceuticals Inc (ACAD) screens constructively on the current data, with an opportunity score of 71/100. The score reflects the available fundamental, technical, valuation and sentiment inputs — it is a research screen, not a forecast or a recommendation to trade.

Bullish case
  • Strong net margin (30%)
  • Revenue growing 50% y/y
  • Low P/E (9×)
Bearish case
  • Weak price momentum
  • Underperforming peers
Potential catalysts
  • Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38
  • Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $28
  • Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40
Horizon: ~1–3 months for technical signals; 12+ months for fundamental quality.
Thesis invalidated if: Momentum reverses and price breaks below its 50-day average; Earnings or guidance disappoint relative to consensus; A sector-level drawdown outweighs stock-specific strength.
News Sentiment
Bullish 75%Neutral 25%Bearish 0%
Recent News
Disclaimer. AI-generated, informational and educational only. Not financial advice. Past performance does not indicate future results.
ACAD Stock Intelligence & Analysis · 360head Stockiq